CC
ALNY icon

Corton Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

Corton Capital’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-946
Closed -$223K – 176
2024
Q4 		$223K Buy
+946
New +$249K 0.13% 225
2024
Q2 		– Sell
-3,004
Closed -$449K – 490
2024
Q1 		$449K Sell
3,004
-1,823
-38% -$304K 0.17% 157
2023
Q4 		$924K Buy
4,827
+3,489
+261% +$594K 0.29% 56
2023
Q3 		$237K Sell
1,338
-1,553
-54% -$296K 0.12% 258
2023
Q2 		$549K Buy
+2,891
New +$573K 0.26% 87

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Corton Capital's ALNY Position: Q1 2025 in Review

Corton Capital sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2025, closing a stake of 946 shares — an estimated $223K sold.

Corton Capital first reported a position in ALNY in Q2 2023 and held it in 5 quarters. The position peaked at $924K in Q4 2023. 627 funds tracked by Wall St. Rank hold ALNY as of Q1 2025.

  • Corton Capital reported no remaining Alnylam Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Corton Capital sold 946 Alnylam Pharmaceuticals shares in Q1 2025, an estimated $223K.
  • Corton Capital first reported a position in Alnylam Pharmaceuticals in Q2 2023 and held it in 5 quarters.
  • Corton Capital's Alnylam Pharmaceuticals position peaked at $924K in Q4 2023.
  • 627 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2025.

Based on Corton Capital's 13F filing for Q1 2025, filed 7 May 2025.